Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$132.01 - $190.29 $7.51 Million - $10.8 Million
-56,900 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$132.13 - $177.45 $2.86 Million - $3.84 Million
-21,638 Reduced 27.55%
56,900 $10.1 Million
Q2 2021

Aug 16, 2021

SELL
$144.0 - $179.73 $8.57 Million - $10.7 Million
-59,492 Reduced 43.1%
78,538 $12.7 Million
Q1 2021

May 14, 2021

BUY
$158.92 - $221.61 $21.9 Million - $30.6 Million
138,030 New
138,030 $23.6 Million
Q3 2020

Nov 13, 2020

SELL
$113.26 - $167.27 $914,234 - $1.35 Million
-8,072 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$72.01 - $120.39 $581,264 - $971,788
8,072 New
8,072 $922,000
Q1 2020

May 13, 2020

SELL
$69.78 - $116.21 $7.56 Million - $12.6 Million
-108,383 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$70.76 - $128.86 $5.49 Million - $10 Million
77,583 Added 251.89%
108,383 $14 Million
Q3 2019

Nov 14, 2019

BUY
$77.91 - $109.6 $2.4 Million - $3.38 Million
30,800 New
30,800 $2.4 Million
Q2 2018

Aug 14, 2018

SELL
$26.05 - $52.4 $226,322 - $455,251
-8,688 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$17.2 - $34.95 $149,433 - $303,645
8,688 New
8,688 $267,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Sofinnova Investments, Inc. Portfolio

Follow Sofinnova Investments, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.